David W. Cescon
David W. Cescon
Medical Oncologist and Clinician Scientist, Princess Margaret Cancer Centre, University of Toronto
Потвърден имейл адрес: uhn.ca
ЗаглавиеПозоваванияГодина
Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area
CM Booth, LM Matukas, GA Tomlinson, AR Rachlis, DB Rose, HA Dwosh, ...
Jama 289 (21), 2801-2809, 2003
10442003
Functional variants of OCTN cation transporter genes are associated with Crohn disease
VD Peltekova, RF Wintle, LA Rubin, CI Amos, Q Huang, X Gu, B Newman, ...
Nature genetics 36 (5), 471, 2004
8982004
Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression
IS Harris, AE Treloar, S Inoue, M Sasaki, C Gorrini, KC Lee, KY Yung, ...
Cancer cell 27 (2), 211-222, 2015
3792015
BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival
C Gorrini, PS Baniasadi, IS Harris, J Silvester, S Inoue, B Snow, PA Joshi, ...
Journal of Experimental Medicine 210 (8), 1529-1544, 2013
1662013
A risk haplotype in the Solute Carrier Family 22A4/22A5 gene cluster influences phenotypic expression of Crohn’s disease
B Newman, X Gu, R Wintle, D Cescon, M Yazdanpanah, X Liu, ...
Gastroenterology 128 (2), 260-269, 2005
1492005
CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours
H Xu, M Di Antonio, S McKinney, V Mathew, B Ho, NJ O’Neil, ...
Nature communications 8, 14432, 2017
1142017
Evolution of the randomized controlled trial in oncology over three decades
CM Booth, DW Cescon, L Wang, IF Tannock, MK Krzyzanowska
Journal of Clinical Oncology 26 (33), 5458, 2008
1142008
Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A.
S Adams, P Schmid, HS Rugo, EP Winer, D Loirat, A Awada, DW Cescon, ...
Journal of Clinical Oncology 35 (15_suppl), 1008-1008, 2017
1132017
Mule/Huwe1/Arf-BP1 suppresses Ras-driven tumorigenesis by preventing c-Myc/Miz1-mediated down-regulation of p21 and p15
S Inoue, Z Hao, AJ Elia, D Cescon, L Zhou, J Silvester, B Snow, IS Harris, ...
Genes & development 27 (10), 1101-1114, 2013
1002013
Functional characterization of CFI-400945, a Polo-like kinase 4 inhibitor, as a potential anticancer agent
JM Mason, DCC Lin, X Wei, Y Che, Y Yao, R Kiarash, DW Cescon, ...
Cancer cell 26 (2), 163-176, 2014
962014
APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation
DW Cescon, B Haibe-Kains, TW Mak
Proceedings of the National Academy of Sciences 112 (9), 2841-2846, 2015
892015
Estrogen controls the survival of BRCA1-deficient cells via a PI3K–NRF2-regulated pathway
C Gorrini, BP Gang, C Bassi, A Wakeham, SP Baniasadi, Z Hao, WY Li, ...
Proceedings of the National Academy of Sciences 111 (12), 4472-4477, 2014
872014
Mutant IDH1 downregulates ATM and alters DNA repair and sensitivity to DNA damage independent of TET2
S Inoue, WY Li, A Tseng, I Beerman, AJ Elia, SC Bendall, F Lemonnier, ...
Cancer cell 30 (2), 337-348, 2016
792016
Genetic polymorphisms and head and neck cancer outcomes: a review
J Hopkins, DW Cescon, D Tse, P Bradbury, W Xu, C Ma, P Wheatley-Price, ...
Cancer Epidemiology and Prevention Biomarkers 17 (3), 490-499, 2008
692008
Phase 2 study of pembrolizumab as first-line therapy for PD-L1–positive metastatic triple-negative breast cancer (mTNBC): preliminary data from KEYNOTE-086 cohort B.
S Adams, S Loi, D Toppmeyer, DW Cescon, M De Laurentiis, R Nanda, ...
Journal of Clinical Oncology 35 (15_suppl), 1088-1088, 2017
682017
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
S Adams, P Schmid, HS Rugo, EP Winer, D Loirat, A Awada, DW Cescon, ...
Annals of Oncology 30 (3), 397-404, 2018
662018
TAp73 is required for spermatogenesis and the maintenance of male fertility
S Inoue, R Tomasini, A Rufini, AJ Elia, M Agostini, I Amelio, D Cescon, ...
Proceedings of the National Academy of Sciences 111 (5), 1843-1848, 2014
612014
LBA13Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from …
S Loi, S Adams, P Schmid, J Cortés, DW Cescon, EP Winer, ...
Annals of Oncology 28 (suppl_5), 2017
572017
Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: a systematic review and meta-analysis
H Goldvaser, TA Barnes, B Šeruga, DW Cescon, A Ocaña, D Ribnikar, ...
JNCI: Journal of the National Cancer Institute 110 (1), 31-39, 2017
562017
p53 Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal cancer prognosis
DW Cescon, PA Bradbury, K Asomaning, J Hopkins, R Zhai, W Zhou, ...
Clinical Cancer Research 15 (9), 3103-3109, 2009
512009
Системата не може да изпълни операцията сега. Опитайте отново по-късно.
Статии 1–20